(CAH) Cardinal Health - Ratings and Ratios
Pharmaceuticals, Medical Devices, Surgical Supplies, Laboratory Products
Dividends
| Dividend Yield | 1.28% |
| Yield on Cost 5y | 5.22% |
| Yield CAGR 5y | -6.01% |
| Payout Consistency | 93.3% |
| Payout Ratio | 22.8% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 23.9% |
| Value at Risk 5%th | 35.6% |
| Relative Tail Risk | -9.69% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.74 |
| Alpha | 55.93 |
| CAGR/Max DD | 2.20 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.567 |
| Beta | 0.325 |
| Beta Downside | 0.291 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.14% |
| Mean DD | 4.51% |
| Median DD | 3.18% |
Description: CAH Cardinal Health December 03, 2025
Cardinal Health, Inc. (NYSE:CAH) is a diversified healthcare services and products firm operating in two primary segments: Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution. The company supplies a broad portfolio-including branded and generic drugs, specialty pharmaceuticals, over-the-counter items, and a wide range of medical-surgical devices such as gloves, needles, and procedure kits-to hospitals, health systems, pharmacies, ambulatory surgery centers, labs, physician offices, and home-care patients.
Beyond distribution, Cardinal Health delivers value-added services: specialty drug management for manufacturers, pharmacy-management solutions for hospitals, and repackaging of generics. It also manufactures and distributes its own branded medical products, assembles sterile and non-sterile kits, and produces radiopharmaceuticals, leveraging integrated technology to streamline direct shipments and supply-chain efficiency.
Key performance indicators to watch include FY 2024 revenue growth (≈ $ 3.5 billion YoY increase in the Pharmaceutical segment), operating cash flow (≈ $ 2.2 billion) and the gross margin trend, which reflects pricing pressure from generic competition and rebate dynamics. A critical sector driver is the ongoing shift toward outpatient care and specialty drug utilization, which fuels demand for Cardinal’s specialty-pharmacy services and high-margin medical-device offerings.
For a deeper dive into how Cardinal Health’s supply-chain innovations compare with peers, exploring ValueRay’s analytical platform can provide actionable insights without the fluff.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (1.59b TTM) > 0 and > 6% of Revenue (6% = 14.06b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 5.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -0.74% (prev -0.79%; Δ 0.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 5.02b > Net Income 1.59b (YES >=105%, WARN >=100%) |
| Net Debt (4.44b) to EBITDA (3.26b) ratio: 1.36 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (239.0m) change vs 12m ago -2.45% (target <= -2.0% for YES) |
| Gross Margin 3.66% (prev 3.36%; Δ 0.30pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 476.8% (prev 520.9%; Δ -44.11pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.21 (EBITDA TTM 3.26b / Interest Expense TTM 263.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.26
| (A) -0.03 = (Total Current Assets 38.54b - Total Current Liabilities 40.27b) / Total Assets 55.23b |
| (B) 0.02 = Retained Earnings (Balance) 1.12b / Total Assets 55.23b |
| (C) 0.05 = EBIT TTM 2.42b / Avg Total Assets 49.14b |
| (D) 0.06 = Book Value of Equity 3.70b / Total Liabilities 57.96b |
| Total Rating: 0.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 73.65
| 1. Piotroski 5.0pt |
| 2. FCF Yield 8.11% |
| 3. FCF Margin 1.90% |
| 4. Debt/Equity -3.14 |
| 5. Debt/Ebitda 1.36 |
| 6. ROIC - WACC (= 28.39)% |
| 7. RoE -55.00% |
| 8. Rev. Trend 88.69% |
| 9. EPS Trend 75.26% |
What is the price of CAH shares?
Over the past week, the price has changed by -6.33%, over one month by +1.04%, over three months by +33.38% and over the past year by +64.19%.
Is CAH a buy, sell or hold?
- Strong Buy: 9
- Buy: 2
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the CAH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 214.7 | 8% |
| Analysts Target Price | 214.7 | 8% |
| ValueRay Target Price | 284.3 | 43% |
CAH Fundamental Data Overview November 29, 2025
P/E Trailing = 32.0634
P/E Forward = 21.8818
P/S = 0.2152
P/B = 16.0657
P/EG = 2.0262
Beta = 0.644
Revenue TTM = 234.31b USD
EBIT TTM = 2.42b USD
EBITDA TTM = 3.26b USD
Long Term Debt = 8.98b USD (from longTermDebt, last quarter)
Short Term Debt = 52.0m USD (from shortTermDebt, last quarter)
Debt = 9.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.44b USD (from netDebt column, last quarter)
Enterprise Value = 54.87b USD (50.43b + Debt 9.03b - CCE 4.59b)
Interest Coverage Ratio = 9.21 (Ebit TTM 2.42b / Interest Expense TTM 263.0m)
FCF Yield = 8.11% (FCF TTM 4.45b / Enterprise Value 54.87b)
FCF Margin = 1.90% (FCF TTM 4.45b / Revenue TTM 234.31b)
Net Margin = 0.68% (Net Income TTM 1.59b / Revenue TTM 234.31b)
Gross Margin = 3.66% ((Revenue TTM 234.31b - Cost of Revenue TTM 225.72b) / Revenue TTM)
Gross Margin QoQ = 3.62% (prev 3.66%)
Tobins Q-Ratio = 0.99 (Enterprise Value 54.87b / Total Assets 55.23b)
Interest Expense / Debt = 0.89% (Interest Expense 80.0m / Debt 9.03b)
Taxrate = 24.08% (144.0m / 598.0m)
NOPAT = 1.84b (EBIT 2.42b * (1 - 24.08%))
Current Ratio = 0.96 (Total Current Assets 38.54b / Total Current Liabilities 40.27b)
Debt / Equity = -3.14 (negative equity) (Debt 9.03b / totalStockholderEquity, last quarter -2.88b)
Debt / EBITDA = 1.36 (Net Debt 4.44b / EBITDA 3.26b)
Debt / FCF = 1.00 (Net Debt 4.44b / FCF TTM 4.45b)
Total Stockholder Equity = -2.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.89% (Net Income 1.59b / Total Assets 55.23b)
RoE = -55.00% (negative equity) (Net Income TTM 1.59b / Total Stockholder Equity -2.90b)
RoCE = 39.82% (EBIT 2.42b / Capital Employed (Equity -2.90b + L.T.Debt 8.98b))
RoIC = 34.61% (NOPAT 1.84b / Invested Capital 5.31b)
WACC = 6.22% (E(50.43b)/V(59.46b) * Re(7.21%) + D(9.03b)/V(59.46b) * Rd(0.89%) * (1-Tc(0.24)))
Discount Rate = 7.21% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.43%
[DCF Debug] Terminal Value 78.77% ; FCFE base≈3.10b ; Y1≈3.21b ; Y5≈3.64b
Fair Price DCF = 269.1 (DCF Value 63.93b / Shares Outstanding 237.6m; 5y FCF grow 3.48% → 3.0% )
EPS Correlation: 75.26 | EPS CAGR: 20.43% | SUE: 4.0 | # QB: 1
Revenue Correlation: 88.69 | Revenue CAGR: 9.56% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.69 | Chg30d=-0.002 | Revisions Net=-2 | Analysts=14
EPS current Year (2026-06-30): EPS=9.83 | Chg30d=+0.396 | Revisions Net=+15 | Growth EPS=+19.3% | Growth Revenue=+16.1%
EPS next Year (2027-06-30): EPS=11.07 | Chg30d=+0.444 | Revisions Net=+15 | Growth EPS=+12.6% | Growth Revenue=+8.3%
Additional Sources for CAH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle